CIN: L15142RJ1991PLC006353
SARDA PROTEINS LTD.

14th August, 2025
To
The Manager
BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai - 400 001

Sub: Outcome of Board Meeting held on Thursday, 14th August, 2025

Ref: Scrip Code: 519242 | Scrip Name: SRDAPRT

Dear Sir/Madam,

We hereby inform you that as per Regulation 30 and 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, the Board of Directors of the Company at their board meeting held today i.e., Thursday, 14th August, 2025, has inter-alia, considered and approved the following items:

1. The Unaudited Financial Results for the Quarter ended 30th June, 2025.

The Financial Results have been subject to limited review by M/s. S K Agarwal & Associates, Statutory Auditor of the Company. A copy of said Financial Results and Limited Review Report issued by the Auditors is enclosed herewith.

The above information will also be hosted on the website of the Company; www.sardaproteins.com. in due course.

The Board Meeting commenced at 02:00 p.m. and concluded at 4.15 p.m. on the same day.

You are requested to take note of the above.
Thanking You,

Yours Faithfully,
For SARDA PROTEINS LIMITED;

KHILAN SAVALIYA
Director
DIN: 08790209

Sarda Proteins Limited Rajasthan

Reg. Office: B-536-537, Matsya Industrial Area, Alwar- 301030 (Rajasthan)
Corp. office: Inside Data Ingenious Global Limited, Station Road, Durgapura, Jaipur-302018 (Rajasthan)
Contact No.: +91-7737822222; **E Mail:** sardaproteins@yahoo.com; **Web:** www.sardaproteins.com

Enclosures:-

1. Unaudited Financial Results for the Quarter ended 30th June, 2025.
2. Limited Review Report on Unaudited Financial Results for the Quarter ended 30th June, 2025.

S K AGARWAL & ASSOCIATES
Chartered Accountants
111, Ist Floor, Ganpati Mall, Samtal Road, Bhiwadi-301019 (Raj.)
Mob : 9828115580 | Email : cabhiwadi@gmail.com

Limited Review Report
Unaudited Standalone Quarterly Results

To
The Board of Directors
Sarda Proteins Ltd

We have reviewed the accompanying statement of unaudited financial results of **SARDA PROTEINS LTD** for the Quarter ended on 30th June, 2025. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S K Agarwal & Associates
Chartered Accountants
FRN: 014841C

S.K. AGARWAL AND ASSOCIATES
CA INDIA
FRN 014841C
BHIWADI

CA Sushil Kumar Agarwal
Partner
M. No.: 403073
UDIN : 25403073BMJOHH5122
Place : Rajkot
Date : 14.08.2025

SARDA PROTEINS LTD
CIN: L15142RJ1991PLC006353
Reg Off: B-536-537, Matsya Industrial Area, Alwar-301030 (Rajasthan)
EMail: sardaproteins@yahoo.com, **website:** www.sardaproteins.com

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2025

Rs.in Lakhs

	Particulars	Three Months Ended on	Preceding Three Months Ended on	Corresponding Three Month	Year Ended
		30.06.2025	31.03.2025	30.06.2024	31.03.2025
		Un-Audited	Un-Audited	Un-Audited	Audited
I.	Revenue from operations	1,095.46	-	-	2,419.10
II.	Other Income	0.08	-	-	0.06
III.	**Total Revenue (I+II)**	**1,095.54**	-	-	**2,419.17**
IV.	Expenses:				
	Cost of Material Consumed	-	-	-	-
	Purchase of Stock -in- Trade	1,128.54	-	-	2,391.07
	Changes in Inventories (Finished Goods, WIP, Stock-in-Trade)	-	-	-	-
	Employee Benefit Expenses	0.75	0.77	4.22	8.94
	Finance Cost	-	-	-	-
	Depreciation and Amoritsation Expenses	-	-	-	-
	Other expenses	15.59	8.95	3.78	17.15
	Total Expenses (IV)	**1,144.88**	**9.72**	**8.01**	**2,417.15**
V.	Profit/(Loss) before Exceptional and Extraordinary Items and Tax (III-IV)	(49.34)	(9.72)	(8.01)	2.02
VI.	Exceptional Items	-	-	-	-
VII.	Profit/(Loss) before Extraordinary Items and Tax (V-VI)	**(49.34)**	**(9.72)**	**(8.01)**	**2.02**
VIII.	Extraordinary Items	-	-	-	-
IX.	Profit/(Loss) before Tax (V-VI)	**(49.34)**	**(9.72)**	**(8.01)**	**2.02**
X.	Tax Expense:				
	(1) Current Tax	-	-	-	-
	(2) Deferred Tax	-	(1.51)	-	(1.51)
XI.	Profit/(Loss) for the period from Continuing Operations (VII-VIII)	**(49.34)**	**(11.23)**	**(8.01)**	**0.51**
XII.	Profit/(Loss) from Discontinued Operations	-	-	-	-
XIII.	Tax Expenses of Discontinued Operations	-	-	-	-
XIV.	Profit/(Loss) from Discontinued Operations (after tax) (X-XI)	-	-	-	-
XV.	Profit/(Loss) for the period (IX+XII)	**(49.34)**	**(11.23)**	**(8.01)**	**0.51**
XVI.	Other Comprehensive Income				
	A (i) Items will not be reclassified to Profit or Loss	-	-	-	-
	(ii) Income Tax relating to items that will not be reclassified to Profit or Loss	-	-	-	-
	B (i) Items will be reclassified to Profit or Loss	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to Profit or Loss	-	-	-	-
XVII.	**Total Comprehensive Income for the period (XIII+XIV)(Comprising Profit (Loss) and other comprehensive income for the period)**	**(49.34)**	**(11.23)**	**(8.01)**	**0.51**
	Paid up Equity Share Capital (Face Value of the Share-Rs. 10 Per Share)	172.59	172.59	172.59	172.59
XVIII	Earnings per Equity Share				
	(1) Basic	(2.86)	(0.65)	(0.46)	0.03
	(2) Diluted	(2.86)	(0.65)	(0.46)	0.03

Notes:

1. The above results were approved by Audit Committee in their meeting held on 10th August 2024 and by Board of Directors in their meeting held on 14th August 2025.
2. Equity Share Capital includes Rs. 77.86 Lakhs as Share Forfeiture Account.
3. Segment Results as per AS is not applicable as dealing in only one segment i.e. "Renewable Energy Sector Solar Cell Products".
4. No Investor Complaints were received during the quarter ended 30-Jun-2025 nor any pending as on 01-Jul-2025.
5. Figures for the previous period have been regrouped wherever considered necessary so as to confirm to the classification of the current period.

For S K Agarwal & Associates
Chartered Accountants
FRN: 014841C

S.K. AGARWAL AND ASSOCIATES CA INDIA FRN 014841C BHIWADI

CA Sushil Kumar Agarwal
Partner
M. No.: 403073
Place: Rajkot
Date: 14-August-2025
UDIN: 25403073BMJOHH5122

On behalf of the Board
Sarda Proteins Ltd

Thumar

Chirag Shantilal Thumar
Managing Director
DIN: 10640822